Sub Banner Image

This Psychedelic Drug Flopped on Trial Results. Should You Buy the Dip?

Equities

Nauman Khan

·

June 29, 2025

·

Barchart

Compass Pathways took a 50% on June 23 hit after a lukewarm trial, but long-term bulls see upside in psychedelics.

More from

Barchart

More

Equities

Articles

Trending News

Enjoy premium content in your inbox.

You're in! Check your email to learn more.
Oops! Something went wrong while submitting the form.